Charlotte, NC2 Active Studies

Myeloproliferative Neoplasms Clinical Trials in Charlotte, NC

Find 2 actively recruiting myeloproliferative neoplasms clinical trials in Charlotte, NC. Connect with local research sites and explore new treatment options.

2
Active Trials
2
Sponsors
314
Enrolling

Recruiting Myeloproliferative Neoplasms Studies in Charlotte

About Myeloproliferative Neoplasms Clinical Trials in Charlotte

Myeloproliferative neoplasms (MPNs) are blood cancers in which the bone marrow overproduces red blood cells, platelets, or white blood cells. Types include polycythemia vera, essential thrombocythemia, and myelofibrosis. Treatment depends on the specific type and risk factors.

There are currently 2 myeloproliferative neoplasms clinical trials recruiting participants in Charlotte, NC. These studies are seeking a combined 314 participants. Research is being sponsored by Merck Sharp & Dohme LLC, John Mascarenhas. Clinical trial participation is free and participants receive study-related medical care at no cost.

Myeloproliferative Neoplasms Clinical Trials in Charlotte — FAQ

Are there myeloproliferative neoplasms clinical trials in Charlotte?

Yes, there are 2 myeloproliferative neoplasms clinical trials currently recruiting in Charlotte, NC. Browse the studies on this page to find one that fits.

How do I join a clinical trial in Charlotte?

Browse the studies listed above, click one that interests you, and complete the free eligibility form. A study coordinator at the Charlotte research site will contact you about next steps.

Are clinical trials in Charlotte free?

Yes, clinical trial participation is always free. Study-related treatment, medical tests, and doctor visits are provided at no cost. Many Charlotte studies also compensate for your time and travel.

What myeloproliferative neoplasms treatments are being tested?

The 2 active trials in Charlotte are testing new therapies including novel drugs, biologics, and treatment approaches for myeloproliferative neoplasms.

Data updated March 2, 2026 from ClinicalTrials.gov